> Home > The Foundation > Champalimaud Centre for the Unknown > Director

Director

"The Champalimaud Centre for the Unknown is committed to advancing cure of human disease via translational and clinical science."

Dr. Zvi Fuks, Director of the Champalimaud Centre for the Unknown

Dr. Zvi Fuks graduated from Hebrew University-Hadassah Medical School in Jerusalem (1962). After serving as member of the academic faculty at Stanford University in California, he was appointed as Professor and Chairman of the Department of Radiation and Medical Oncology at the Hebrew University-Hadassah Medical School in Jerusalem (1976-1984). He subsequently served as Chairman of the Department of Radiation Oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York (1984-1998 and 2004-2005), and its Deputy Physician-in-Chief for Planning (1998-2004). Currently, Dr Fuks serves as Director of the Champalimaud Centre for the Unknown in Lisbon, Portugal.

Dr. Fuks is a physician-scientist, renown for contributions to advance the cure of Hodgkin’s disease, lymphoma, ovarian and prostate cancers. He is also recognized for pioneering the development of three-dimensional conformal radiotherapy (3D-CRT), intensity modulated radiation therapy (IMRT) and single dose image guided radiotherapy (SD-IGRT), receiving several awards for advancing the cure of human cancer via the clinical implementation of these modalities. Important discoveries resulting from his laboratory research include the role of growth factors in regulating tumor cell invasion, the mechanism of the ASMase/ceramide pathway in the apoptotic response to radiation, and the role of microvascular dysfunction as critical epigenetic regulator of tumor cell lethality by high single dose radiation. The latter studies provided a biologic basis for the application of single-dose radiotherapy as the current most advanced mode of cancer cure by radiotherapy.

Dr Fuks is also recognized for his engagement in planning and implementation of cancer treatment facilities in Israel, Europe and the USA. Specifically, he established and was the first Director of the Sharett Institute of Oncology of the Hebrew University-Hadassah Medical School in Jerusalem, built the Radiation Therapy Center at Memorial Sloan-Kettering Cancer Center in New York, and served as a senior advisor, in charge of professional planning of the Davidoff Cancer Center of the Tel Aviv University as a premier cancer care facility in Israel. Since 2010 he has been engaged in planning and training the professional team of a new cancer center at OAO Medicina in Moscow, Russia, and currently he directs the implementation of the Champalimaud Centre for the Unknown as state-of-the art cancer research and treatment center in Lisbon, Portugal.

Dr. Fuks is a member of numerous professional societies, and is the recipient of multiple honors and awards. He is the incumbent of the Alfred P. Sloan Chair at Memorial Sloan Kettering Cancer Center, the recipient of the Klaas Breuer Gold Medal Award, the Sir James Carreras Award, the Probstein Oncology Awards, the Elis Berven Award, the Gold Medal Award of the American Society for Therapeutic Radiation and Oncology, The Folke Edsmyr Award of the Karolinska Institute in Sweden, the Society of Memorial Sloan-Kettering Cancer Center Award for Excellence in Medicine, the Willet F. Whitmore Award for Clinical Excellence, the Honorary Award of the Canadian Association of Radiation Oncologists, and the Juan A. del Regato Gold Medal Award. In 2010, Dr. Fuks was inducted as a member to the Institute of Medicine of the National Academies, USA. Dr. Fuks published over 400 peer-reviewed scientific research articles and over 100 book chapters.